Antiulcerogenic and antibacterial activities of Apium graveolens essential oil and extract.

This study investigates the antiulcerogenic and antibacterial activities of Apium graveolens extracts. The antiulcerogenic activity was evaluated in rats by the HCl/EtOH method. Inhibition of gastric lesions by A. graveolens extracts was dose-dependent for both aerial part (53-76%) and seeds (51-95%). The methanolic extract as well as the aqueous extracts used at 300 mg kg(-1) dose exhibited a highly significant inhibition of gastric lesions (91% and 95%, respectively) which was similar to that induced by omeprazole (94%). Essential oil and aqueous extract prepared from the aerial parts of A. graveolens were tested to determine their antibacterial activity using the paper disc-diffusion method, the minimal inhibitory concentration and the minimal bactericidal concentration. Essential oil of A. graveolens was strongly inhibitory against Escherichia coli and moderately inhibitory against Pseudomonas aeruginosa and Staphylococcus aureus. The chemical composition of the volatile oil was investigated by gas chromatography analysis. The major components identified were ß-pinene, camphene, cumene, limonene, α-thuyene, α-pinene, ß-phellendrene, p-cymene, γ-terpinene, sabinene and terpinolene.

External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection.

Jean-Pierre Allain and colleagues argue that, while unintended, the foreign aid provided for blood transfusion services in sub-Saharan Africa has resulted in serious negative outcomes, which requires reflection and rethinking.

A novel hepatitis B virus subgenotype, D7, in Tunisian blood donors.

Tunisia is a medium-level epidemic country for hepatitis B virus (HBV). This study characterizes, for the first time, full genome HBV strains from Tunisia. Viral load quantification and phylogenetic analyses of full genome or pre-S/S sequences were performed on 196 hepatitis B surface antigen (HBsAg)-positive plasma samples from Tunisian blood donors. The median viral load was 64.65 IU ml(-1) (range<5-7.7x10(8) IU ml(-1)) and 89% of samples had viral loads below 10,000 IU ml(-1). Fifty-nine strains formed a novel subgenotype D7, 41 strains clustered in subgenotype D1, seven strains in subgenotype A2 and one strain in genotype C. The novel subgenotype D7 was defined by maximum Bayesian posterior probability, a genetic divergence from other HBV/D subgenotypes by >4% and a stronger HBV/E signal in the X to core genes than subgenotype D1. In conclusion, HBV/D is dominant in asymptomatic Tunisian HBsAg carriers and a novel subgenotype, D7, was the most common subgenotype found in this population.

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.

From April 2003 to December 2006, 195 patients with de novo symptomatic myeloma and younger than 60 years of age were randomly assigned to receive either tandem transplantation up front (arm A, n = 97) or one autologous stem-cell transplantation followed by a maintenance therapy with thalidomide (day + 90, 100 mg per day during 6 months) (arm B, n = 98). Patients included in arm B received a second transplant at disease progression. In both arms, autologous stem-cell transplantation was preceded by first-line therapy with thalidomide-dexamethasone and subsequent collection of peripheral blood stem cells with high-dose cyclophosphamide (4 g/m(2)) and granulocyte colony stimulating factor. Data were analyzed on an intent-to-treat basis. With a median follow-up of 33 months (range, 6-46 months), the 3-year overall survival was 65% in arm A and 85% in arm B (P = .04). The 3-year progression-free survival was 57% in arm A and 85% in arm B (P = .02). Up-front single autologous transplantation followed by 6 months of maintenance therapy with thalidomide (with second transplant in reserve for relapse or progression) is an effective therapeutic strategy to treat multiple myeloma patients and appears superior to tandem transplant in this setting. This study was registered at www.ClinicalTrials.gov as (NCT 00207805).

[A cord blood bank in Tunisia: usefulness and feasibility]. / Mise en place d'une banque de sang placentaire en Tunisie: utilite et faisabilite.

BACKGROUND: The cord blood is a souce of hematopoietic stem cells. This have encouraged the creation of many cord blood banks around the world. THE AIM: By this prospective study during 2 years, we tried to show the advantages of such sources of progenitors ,and to evaluate our techniques of collection, freezing, biological and microbiological survey. METHODS: For this aim, we tested 100 specimens of cord blood before and after defrosting. Our selection criteria were a volume > or = 60 ml, a CD 34+ cells count > or = 2.10(6), bacteriological and serological negativity. RESULTS: This 100 specimens have an average volume of 95.22 ml, an average nuclear cells count of 10.95.108 and an average CD 34+ cells count of 2.96. 10(6) The average cells viability after defrosting is 96.69%, and the average efficiency rate of 92.11%. The specimens selected according to our selection criterias were of 39%. CONCLUSION: Our results confirm the feasibility of a cord blood bank in the "Centre National de Transfusion Sanguine" in Tunis.